Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Janneke S. Hoogstad-van Evert"'
Autor:
Ralph J. A. Maas, Janneke S. Hoogstad-van Evert, Iris M. Hagemans, Jolanda Brummelman, Diede van Ens, Paul K. J. D. de Jonge, Laura Hooijmaijers, Shweta Mahajan, Anniek B. van der Waart, Charlotte K. J. C. Hermans, Janne de Klein, Rob Woestenenk, Antonius E. van Herwaarden, Nicolaas P. M. Schaap, Somayeh Rezaeifard, Daniele V. F. Tauriello, Petra L. M. Zusterzeel, Nelleke Ottevanger, Joop H. Jansen, Willemijn Hobo, Harry Dolstra
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Natural killer (NK) cell therapy represents an attractive immunotherapy approach against recurrent epithelial ovarian cancer (EOC), as EOC is sensitive to NK cell-mediated cytotoxicity. However, NK cell antitumor activity is dampened by suppressive f
Externí odkaz:
https://doaj.org/article/fba2485f4f604077a2047c69ad71b92f
Autor:
Jolien M.R. Van der Meer, Paul K.J.D. de Jonge, Anniek B. van der Waart, Alexander C. Geerlings, Jurgen P. Moonen, Jolanda Brummelman, Janne de Klein, Malou C. Vermeulen, Ralph J.A. Maas, Nicolaas P.M. Schaap, Janneke S. Hoogstad-van Evert, Petronella B. Ottevanger, Joop H. Jansen, Willemijn Hobo, Harry Dolstra
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Combining natural killer (NK) cell adoptive transfer with tumor-sensitizing chemotherapy is an attractive approach against recurrent ovarian cancer (OC), as OC is sensitive to NK cell-mediated immunity. Previously, we showed that CD34+ hematopoietic
Externí odkaz:
https://doaj.org/article/619acac2e57b40f7a452e2426b67db92
Autor:
Janneke S. Hoogstad-van Evert, Jeannette Cany, Dirk van den Brand, Manon Oudenampsen, Roland Brock, Ruurd Torensma, Ruud L. Bekkers, Joop H. Jansen, Leon F. Massuger, Harry Dolstra
Publikováno v:
OncoImmunology, Vol 6, Iss 8 (2017)
Adoptive transfer of allogeneic natural killer (NK) cells is an attractive therapy approach against ovarian carcinoma. Here, we evaluated the potency of highly active NK cells derived from human CD34+ haematopoietic stem and progenitor cells (HSPC) t
Externí odkaz:
https://doaj.org/article/dba8270971e34cc5b11540e0c4f58ebb
Autor:
Ralph Ja Maas, Janneke S Hoogstad-van Evert, Jolien Mr Van der Meer, Vera Mekers, Somayeh Rezaeifard, Alan J Korman, Paul Kjd de Jonge, Jeannette Cany, Rob Woestenenk, Nicolaas Pm Schaap, Leon F Massuger, Joop H Jansen, Willemijn Hobo, Harry Dolstra
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-in
Externí odkaz:
https://doaj.org/article/2eddf0d46af94ea7b8105cc99fe02594
Autor:
Jolien M R, Van der Meer, Paul K J D, de Jonge, Anniek B, van der Waart, Alexander C, Geerlings, Jurgen P, Moonen, Jolanda, Brummelman, Janne, de Klein, Malou C, Vermeulen, Ralph J A, Maas, Nicolaas P M, Schaap, Janneke S, Hoogstad-van Evert, Petronella B, Ottevanger, Joop H, Jansen, Willemijn, Hobo, Harry, Dolstra
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Combining natural killer (NK) cell adoptive transfer with tumor-sensitizing chemotherapy is an attractive approach against recurrent ovarian cancer (OC), as OC is sensitive to NK cell-mediated immunity. Previously, we showed that CD34+ hematopoietic
Autor:
Janne de Klein, Paul K J D de Jonge, Willemijn Hobo, Nicolaas Schaap, Jurgen P Moonen, Alexander C Geerlings, Janneke S. Hoogstad-van Evert, Jolien M R van der Meer, Harry Dolstra, Anniek B. van der Waart, Malou C Vermeulen, Joop H. Jansen, Jolanda Brummelman, Petronella B. Ottevanger, Ralph J. A. Maas
Publikováno v:
Oncoimmunology, 10
OncoImmunology, Vol 10, Iss 1 (2021)
Oncoimmunology, 10, 1
OncoImmunology, Vol 10, Iss 1 (2021)
Oncoimmunology, 10, 1
Combining natural killer (NK) cell adoptive transfer with tumor-sensitizing chemotherapy is an attractive approach against recurrent ovarian cancer (OC), as OC is sensitive to NK cell-mediated immunity. Previously, we showed that CD34+ hematopoietic
Autor:
Rob Woestenenk, Vera E. Mekers, Jeannette Cany, Somayeh Rezaeifard, Alan J. Korman, Nicolaas Schaap, Paul K J D de Jonge, Joop H. Jansen, Harry Dolstra, Janneke S. Hoogstad-van Evert, Leon F.A.G. Massuger, Jolien M R van der Meer, Ralph J. A. Maas, Willemijn Hobo
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
Oncoimmunology, 9, 1
Oncoimmunology, 9
OncoImmunology, Vol 9, Iss 1 (2020)
article-version (VoR) Version of Record
Oncoimmunology, 9, 1
Oncoimmunology, 9
OncoImmunology, Vol 9, Iss 1 (2020)
Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-in
Autor:
Ruud L.M. Bekkers, Janneke S. Hoogstad-van Evert, Harry Dolstra, Leon F.A.G. Massuger, Nelleke Ottevanger, Joop H. Jansen
Publikováno v:
Gynecologic Oncology, 157, 810-816
Gynecologic Oncology, 157, 3, pp. 810-816
Gynecologic Oncology, 157, 3, pp. 810-816
Contains fulltext : 220786.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Adoptive cellular immunotherapy could be an interesting new treatment option for ovarian carcinoma (OC), as research has demonstrated that OC is an immunogenic diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a06461f76f2fed616c4bd9ec2271a1
http://hdl.handle.net/2066/220786
http://hdl.handle.net/2066/220786
Autor:
Sophieke C.H.A. van der Steen, Jolien M R van der Meer, Willemijn Hobo, Jeannette Cany, Ralph J. A. Maas, Leon F.A.G. Massuger, Harry Dolstra, Ruud L.M. Bekkers, Janneke S. Hoogstad-van Evert, Jeffrey S. Miller, Joop H. Jansen
Publikováno v:
Oncotarget, 9, 78, pp. 34810-34820
Oncotarget, 9, 34810-34820
Oncotarget
Oncotarget, 9, 34810-34820
Oncotarget
The demonstration that ovarian carcinoma (OC) is an immunogenic disease, opens opportunities to explore immunotherapeutic interventions to improve clinical outcome. In this regard, NK cell based immunotherapy could be promising as it has been demonst
Autor:
William P.J. Leenders, Lina Wübbeke, Seppo Ylä-Herttuala, Rike Wallbrecher, Dirk van den Brand, Janneke S. Hoogstad-van Evert, Sanne A. M. van Lith, Leon F.A.G. Massuger, Sander M. J. van Duijnhoven, Petri I. Mäkinen, Roland Brock
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics, 124, 63-72
European Journal of Pharmaceutics and Biopharmaceutics, 124, pp. 63-72
European Journal of Pharmaceutics and Biopharmaceutics, 124, pp. 63-72
Photodynamic therapy (PDT) is an emerging method to treat light-accessible malignancies. To increase specificity and allow dose reduction, conjugates of photosensitizers (PS) with antibodies against tumor-associated antigens have been developed for p